Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer.
Aaron J Bernstein,
Renske Keeman,
Amber N Hurson,
Fiona M Blows,
Manjeet K Bolla,
Jodi L Miller,
Roger L Milne,
Hugo Horlings,
Alexandra J van den Broek,
Clara Bodelon,
James M Hodge,
Alpa V Patel,
Lauren R Teras,
Federico Canzian,
Rudolf Kaaks,
Hermann Brenner,
Ben Schöttker,
Sabine Behrens,
Jenny Chang-Claude,
Tabea Maurer,
Nadia Obi,
Fergus J Couch,
H Raza Ali,
Carlos Caldas,
Irene Andrulis,
Gord Glendon,
Anna Marie Mulligan,
Wilma Mesker,
Agnes Jager,
Annette Heemskerk-Gerritsen,
Peter Devilee,
Scott M Lawrence,
Jolanta Lissowska,
Karun Mutreja,
Thomas Ahearn,
Stephen Chanock,
Maire A Duggan,
Diana Eccles,
J Louise Jones,
Will Tapper,
Antoinette Hollestelle,
Maartje Hooning,
John Martens,
Carolien H M van Deurzen,
Angela Cox,
Simon S Cross,
Mikael Hartman,
Jingmei Li,
Thomas C Putti,
Ute Hamann,
Muhammad Rashid,
Ania Jakubowska,
Nicki Camp,
Melissa H Cessna,
Amy Berrington de Gonzalez,
Katarzyna Bialkowska,
Jacek Gronwald,
Jan Lubiński,
Siddhartha Yadav,
Pietro Lio,
Douglas F Easton,
Mustapha Abubakar,
Montse Garcia-Closas,
Paul D P Pharoah,
Marjanka K Schmidt
Abstract
Breast cancer immune response is important to patient outcome, but the prognostic interaction between tissue-infiltrating immune cell (TIIC) types is not well-characterized. We evaluated the associations between CD8+, FOXP3+, CD20+, and CD163+ TIICs and breast cancer-specific survival (BCSS). We developed an AI in Halo to score TIIC percentage by compartment (overall, stromal, or intra-tumoral) in 99,051 microarray images from 12,285 female breast cancers. The associations between log-transformed TIIC scores and BCSS were assessed using Cox regression. CD8+ and FOXP3+ TIICs were associated with better BCSS in ER-negative disease; CD8+ and CD20+ TIICs were associated with a better prognosis in ER-positive disease; and CD163+ TIICs were associated with a poorer prognosis in ER-positive disease in multi-marker models. These results may have implications for breast cancer immunotherapy.